title: Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids.
abstract: The human cytochrome P450 (CYP) enzymes play a major role in the metabolism of endobiotics and numerous xenobiotics including drugs. Therefore it is the standard procedure to test new drug candidates for interactions with CYP enzymes during the preclinical development phase. The purpose of this study was to determine in vitro CYP inhibition potencies of a set of isoquinoline alkaloids to gain insight into interactions of novel chemical structures with CYP enzymes. These alkaloids (n=36) consist of compounds isolated from the Papaveraceae family (n=20), synthetic analogs (n=15), and one commercial compound. Their inhibitory activity was determined towards all principal human drug metabolizing CYP enzymes: 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4. All alkaloids were assayed in vitro in a 96-well plate format using pro-fluorescent probe substrates and recombinant human CYP enzymes. Many of these alkaloids inhibited the CYP3A4 form, with 30/36 alkaloids inhibiting CYP3A4 with at least moderate potency (IC₅₀ < 10 μM) and 15/36 inhibiting CYP3A4 potently (IC₅₀ < 1 μM). Among them corydine, parfumine and 8-methyl-2,3,10,11-tetraethoxyberbine were potent and selective inhibitors for CYP3A4. CYP2D6 was inhibited with at least moderate potency by 26/34 alkaloids. CYP2C19 was inhibited by 15/36 alkaloids at least moderate potently, whereas CYP1A2, CYP2B6, CYP2C8, and CYP2C9 were inhibited to a lesser degree. CYP2A6 was not significantly inhibited by any of the alkaloids. The results provide initial structure-activity information about the interaction of isoquinoline alkaloids with major human xenobiotic-metabolizing CYP enzymes, and illustrate potential novel structures as CYP form-selective inhibitors.
authors.affiliation: School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland. kaisa.salminen@uef.fi
authors.forename: Kaisa A
authors.initials: KA
authors.lastname: Salminen
authors.forename: Achim
authors.initials: A
authors.lastname: Meyer
authors.forename: Lenka
authors.initials: L
authors.lastname: Jerabkova
authors.forename: Laura E
authors.initials: LE
authors.lastname: Korhonen
authors.forename: Minna
authors.initials: M
authors.lastname: Rahnasto
authors.forename: Risto O
authors.initials: RO
authors.lastname: Juvonen
authors.forename: Peter
authors.initials: P
authors.lastname: Imming
authors.forename: Hannu
authors.initials: H
authors.lastname: Raunio
mesh_terms: D000470:Alkaloids / Q000302:isolation & purification / Q000494:pharmacology*; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors / Q000302:isolation & purification / Q000494:pharmacology*; D041743:Herb-Drug Interactions; D006801:Humans; D007546:Isoquinolines / Q000302:isolation & purification / Q000494:pharmacology*; D028101:Papaveraceae / Q000737:chemistry*; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D000470:Alkaloids; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D007546:Isoquinolines; D010936:Plant Extracts